NCT04367311
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04367311
Title Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Nasser Hanna
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University Feinberg School of Medicine Chicago Illinois 60611 United States Details
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
Summit Health Berkeley Heights New Jersey 07922 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
New York University Clinical Cancer Center New York New York 10016 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
Penn State Cancer Institute Hershey Pennsylvania 17033 United States Details
University of Virginia Health System Charlottesville Virginia 22908 United States Details
University of Wisconsin Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field